FDA has granted “emergency-use authorization” to Eli Lilly’s coronavirus antibody treatment

The Food and Drug Administration (FDA) gave Eli Lilly’s antibody drug emergency-use authorization on Monday, Nov. 9. Early data has strongly suggested that the pharmaceutical company’s antibody drug is effective at keeping people with mild to moderate cases of the Wuhan coronavirus (COVID-19) from needing to get admitted to a hospital. The FDA extended the emergency approval to the experimental therapy known … Continue reading FDA has granted “emergency-use authorization” to Eli Lilly’s coronavirus antibody treatment

AstraZeneca begins advanced trials for COVID-19 antibody medication

British pharmaceutical company AstraZeneca has commenced late-stage trials for its COVID-19 antibody drug. In an Oct. 9 statement, the company said that two tests for the AZD7442 long-acting antibody drug, involving 6,000 adult participants worldwide, will look at the medication’s ability to prevent COVID-19 symptoms. A subsequent trial to observe AZD7442’s use as a COVID-19 treatment, involving 4,000 volunteers, … Continue reading AstraZeneca begins advanced trials for COVID-19 antibody medication

Eli Lilly monoclonal antibody drug trial paused over safety concerns

Eli Lilly & Company are halting the enrollment of participants in a clinical trial of its antibody treatment for the Wuhan coronavirus (COVID-19) due to safety concerns. According to company spokeswoman Molly McCully, an independent data and safety monitoring board (DSMB) had recommended pausing enrollment in the U.S. government-sponsored trials. Lilly, however, did not say what caused the panel … Continue reading Eli Lilly monoclonal antibody drug trial paused over safety concerns